Risk factors
VERU (VERU) risk factors
Item 1A of every VERU Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors71 risks12 new18 dropped25 reworded
Veru sold its FC2 business and now relies entirely on unapproved drug candidates like enobosarm and sabizabulin.
Filed Dec 17, 2025 - FY2024 10-K risk factors77 risks
Veru's risk profile centers heavily on clinical trial execution and funding risks for enobosarm and sabizabulin. The company faces a going concern warning, Nasdaq delisting notice, and SEC Form S-3 ineligibility affecting capital raises.
Filed Dec 16, 2024